Compare Primo Brands Corporation Class A Common Stock (PRMB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Primo Brands Corporation Class A Common Stock vs GeneDx Holdings Corp — how do they compare? Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Primo Brands Corporation Class A Common Stock is far larger — about 3.5× GeneDx Holdings Corp's market cap, and Primo Brands Corporation Class A Common Stock pays a 2.54% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Primo Brands Corporation Class A Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| PRMB | WGS | |
|---|---|---|
Market Cap | $6.84B | $1.94B |
Volume | 2,864,594 | 524,385 |
Sector | Consumer Staples | Health |
52-Week High | $25.39 | $167.51 |
52-Week Low | $14.46 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $12.17B | $1.97B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
